*CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA®.
†Remicade® is a registered trademark of MSD.
ҩ Therapeutic equivalence of clinical response according to ACR20 criteria was concluded if the 95% CI for the treatment difference was within ± 15%18.
ɣ Primary endpoint.
# ITT population
RA, Rheumatoid Arthritis; CI, Confidence interval; ITT, Intention-to-treat; PP, Per-protocol.
"By clicking "confirm" to create an account, you confirm that the information you have provided above is correct, and you agree to (i) Pfizer’s processing of your personal data, including its transfer internationally and to third parties, in accordance with the Pfizer Privacy and Cookie Policy; and (ii) Pfizer’s Website Terms of Use."